المملكة العربية السعودية
الهيئة العامة للغذاء والدواء

Kingdom of Saudi Arabia
Saudi Food & Drug Authority

Medical Device Sector
Surveillance & Biometrics Executive Department

قطاع الأجهزة والمنتجات الطبية
الإدارة التنفيذية للرقابة والقياسات الحيوية

Safety Communication رسالة سلامة

An elevated imprecision at low concentration range with current reagent lots v2.0

Device/ Product Description:	C-Reactive Protein Gen.3	
Manufacturer:	Roche Diagnostics	
Problem Summary:	Currently available reagent lots of the C-Reactive Protein Gen.3 (CRPL3) assay for cobas c 311/501 (ACN 210), cobas c 502/701/702 (ACN 8210) and cobas c 503 (ACN 20490) show higher test imprecision at lower concentrations on all cobas c systems. In addition, specifically on cobas c 503, a higher frequency of calibration failures due to duplicate error (DUP.E) has been found. For more information, please check the attachment below. If you think you had a problem with your device or a device your patient uses, please report the problem to SFDA through: NCMDR Vigilance system 19999 unified call center	
	AR name:	Roche Diagnostics Saudi Arabia Limited
	Assigned Contact Person:	Turki Abdulaziz Bin Juraid
	Mobile/Phone:	0545673111
	Email:	rdsa.regulatory@roche.com

Quality Notification

24 January 2021

Subject: C-Reactive Protein Gen.3: Slightly elevated imprecision at low concentration range with current reagent lots v2.0

Dear Valued Customer,

Information

Product	GMMI	Lot No.
C-Reactive Protein Gen.3	04956842190 08057575190 05172373190	see table in text

Instrument/System	**cobas c** 311 analyzer **cobas c** 501 module **cobas c** 502 module **cobas c** 503 analytical unit **cobas c** 701 module **cobas c** 702 module
Component	Reagent

Subject

Currently available reagent lots of the C-Reactive Protein Gen.3 (CRPL3) assay for cobas c 311/501 (ACN 210), cobas c 502/701/702 (ACN 8210) and cobas c 503 (ACN 20490) show higher test imprecision at lower concentrations on all cobas c systems. In addition, specifically on cobas c 503, a higher frequency of calibration failures due to duplicate error (DUP.E) has been found.

روش دياجنوستيكس ميدل ايست ش م ح
شركة ذات مسؤولية محدودة تأسست بموجب القانون رقم ٢ سنة ١٩٨٦
ووفقا للائحة التنفيذية رقم ١ لسنة ١٩٩٩
رقم السجل التجاري: ١٥٠٤١٦ –رقم الرخصة: ١٣٠٢٩٤
Roche Diagnostics Middle East FZCO
Formed Pursuant to Law No. 2 of 1986
& Implementing Regulation No. 1 of 1999 with Limited Liability
Registration No.: 150416 – License No.: 130294

ص. ب. ٢٦١٠٠١ – المنطقة الحرة لجبل علي
دبي – الإمارات العربية المتحدة
PO Box 261001- Jebel Ali Free Zone
Dubai, United Arab Emirates

هاتف: ٨١٦ ٩٠٠٠ ٤ (٠) ٩٧١+
فاكس: ٨١٦ ٩٠٠١ ٤ (٠) ٩٧١+
Tel. +971 (0) 4 816 9000
Fax +971 (0) 4 816 9001

Internal investigations were performed and specifications are fulfilled or not fulfilled as described below:

Test performance **within specifications** for CRP values above **1.4 mg/L** (for all cobas c systems):

- Method comparison studies
- Linearity studies
- QC recovery
- Within run precision (except cobas c 503, see below)

Specifications **not fulfilled:**

- LoB/LoD/LoQ
- Within run precision in the concentration range of 0.3 mg/L to 1.4 mg/L CRP for cobas c311/501/502/701/702
- Within run precision in the concentration range of 0.3 mg/L to 5 mg/L CRP for cobas c 503
- Calibration failure due to DUP.E on cobas c 503

As recovery of controls, method comparison studies with native samples and linearity studies performed within specifications, there is no medical risk for results from patient samples and there is no impact on the intended use of the product.

It is recommended that customers switch to the Tina-quant® C-Reactive Protein IV (CRP4) assay which is not affected.

The C-Reactive Protein (Latex) (CRPLX) and Cardiac C-Reactive Protein (Latex) High Sensitive (CRPHS) assays are not affected.

The following table gives an overview on currently available reagent lots within shelf life regarding the issue:

Product	**GMMI**	**Lot No., expiry**	**Lot # affected by increased imprecision?**
C-Reactive Protein Gen.3	04956842190 **cobas c** pack small	452045, exp. 2021-03 463518, exp. 2021-05 479885, exp. 2021-08 490025, exp. 2021-08 521125, exp. 2022-02	NOT affected. NOT affected. affected. affected. affected.
	08057575190 **cobas c** pack green	479882, exp. 2021-08 490026, exp. 2021-08 521153, exp. 2022-02	affected. affected. affected.
	05172373190 **cobas c** pack large	452041, exp. 2021-03 463515, exp. 2021-05 479881, exp. 2021-08 490027, exp. 2021-08 521152, exp. 2022-02	NOT affected. NOT affected. affected. affected. affected.

Risk Assessment

Frequency of Occurrence
3 complaints have been escalated. The issue affects all cobas c packs of the reagent lots described as "affected" in the table above.

Detectability
Calibration signals are elevated for setpoint Std. 1 and failed calibrations on cobas c 503 are flagged with DUP.E.

Severity
The consensus reference interval for adults is < 5 mg/L. The described imprecision at low concentrations has no influence on results above the medical decision level. This means there is no risk that patient results above the medical decision level are reported inaccurately too low, i.e. erroneously normal, or that results are reported inaccurately too high, i.e. erroneously abnormal.

Recovery of controls, method comparison studies with native samples and linearity studies performed within specifications.

No patient or diagnostic test results are affected and a medical risk to patients and users can be excluded. Therefore, an HHE is not necessary.

Instructions

- As there is no medical risk to health all reagent lots within shelf life continue to be available for sale.
- Newly produced reagent lots are expected to be subject to release testing from end Feb 2021. The root cause has been addressed and future lots will continue to be monitored.
- Calibrations on cobas c 503 flagged with DUP.E should be repeated in case of calibration failure.
- Switching to CRP4 is recommended as this assay is not affected.

Customer Details:

Facility Name: Contact Name: Position: Phone: Date: Signature and Stamp:

If you have any questions, please do not hesitate to contact our Application Support Team or your local Account Manager.

Yours sincerely,

For on behalf of
Roche Diagnostics Middle East FZCO

Mohammad Al Shuraidi
Quality Manager, Middle East

Marie McMahon
Head of Quality, Regulatory & SHE